Redefining the Real Problem in Psychedelic Trials: Why Fighting the Lessebo Matters More Than Blinding Integrity

Bottom line: In psychedelic research, the problem isn’t that people can guess which treatment they’re getting. It’s that they might be disappointed when they’re not.

Somewhere in a clinical trial, a participant sits quietly, eyes closed, breathing deeply, and wonders if they’re about to receive the real psychedelic or just a sugar pill. The question is more than academic—it’s a psychological trap. For years, researchers have focused on how to prevent participants from guessing their treatment, but a new study suggests the bigger issue is what happens after they find out they’re in the placebo group. The problem isn’t blinding; it’s disappointment. And this revelation is shaking the foundations of how we design and interpret psychedelic trials.

The Blinding Paradox: Why It’s Not the Real Problem

For decades, the gold standard in clinical trials has been blinding—hiding from participants which treatment they’re receiving to prevent bias. In most fields, this is non-negotiable. But in psychedelic research, the debate over blinding is unusually intense. Critics argue that participants can often guess whether they’re getting the real drug or a placebo, and this undermines the validity of the study. However, a new study from the International Journal of Drug Policy challenges this assumption.

The researchers point out that imperfect blinding isn’t unique to psychedelics. In randomized trials across all medical disciplines, participants frequently guess their treatment allocation. Yet, blinding integrity is rarely scrutinized outside of psychedelic research. This suggests a double standard: while other trials accept some level of guesswork, psychedelic trials are held to an impossible standard.

But here’s the twist: the problem isn’t just that people can guess their treatment. It’s that once they know they’re in the placebo group, they might feel disappointed. This is where the concept of “lessebo”—a negative placebo effect—comes in. Lessebo is not just about expecting nothing; it’s about feeling let down when you’re told you’re not getting the real thing.

The study argues that this disappointment is a critical factor in the outcomes of psychedelic trials. When participants in the placebo group feel they’ve been shortchanged, their psychological state can skew the results. This isn’t just an academic concern—it’s a real, measurable effect that can muddy the data and complicate the interpretation of what the psychedelic actually does.

Lessebo: The Disappointment That Doesn’t Just Feel Bad

Lessebo, a term coined by researchers in the field, refers to a negative placebo effect. Unlike the traditional placebo effect, where people feel better because they believe they’re receiving treatment, lessebo is the opposite. It occurs when participants in the control group—those who receive a placebo—feel disappointment, frustration, or even anger because they were not given the active treatment.

This phenomenon is not limited to psychedelic trials. In other medical contexts, disappointment can also influence outcomes. For example, in trials for antidepressants or pain management, participants who receive a placebo might report worse symptoms simply because they feel they’ve been denied something they expected. However, in psychedelic research, the stakes are higher. The experience of a psychedelic is often described as transformative, and the expectation of a meaningful experience is deeply ingrained in the participants.

The study highlights that the risk of lessebo is not just about pre-treatment expectations. It’s also about how the trial is structured. If participants are not properly prepared for the possibility of receiving a placebo, they may feel betrayed when they find out. This emotional response can have a measurable impact on their psychological state and, by extension, their reported outcomes.

The researchers argue that the key to mitigating lessebo is not just about improving blinding, but about managing expectations. If participants are informed that they might be in the placebo group, and that this is a standard part of the trial, they are less likely to feel disappointed. This requires a shift in how trials are designed and communicated.

The Ethical Implications of Lessebo: More Than Just Data

The study raises important ethical questions about how we conduct psychedelic trials. If participants are more likely to experience negative effects when they’re in the placebo group, then the design of the trial itself can influence the results. This means that the way we structure the trial—whether we use active placebos, double-blinding, or open-label designs—can have a significant impact on the data we collect.

Moreover, the study points out that the current emphasis on perfect blinding may be misguided. While blinding is important for reducing bias, it’s not the only factor that affects the validity of the trial. The emotional and psychological state of participants can also play a role. This means that researchers need to consider not just the scientific validity of the trial, but also the ethical implications of how participants are treated.

The researchers propose that future trials should focus on managing expectations rather than trying to perfect blinding. This could involve structured psychoeducation before the trial, stronger therapeutic alliances with participants, and more realistic preparation for the possibility of receiving a placebo. By doing so, researchers can reduce the risk of lessebo and improve the overall quality of the data.

Frequently Asked Questions

Q: Is blinding still important in psychedelic trials?
A: Yes, but not as the sole focus. Blinding is still important for reducing bias, but the study argues that it’s not the only factor that affects the validity of the trial. Managing expectations and reducing disappointment are equally important.

Q: How can we prevent lessebo in psychedelic trials?
A: The study suggests that structured psychoeducation, stronger therapeutic alliances, and realistic preparation for the possibility of receiving a placebo can help reduce the risk of lessebo. These strategies can help participants feel more prepared and less disappointed.

Q: Does this mean we should stop blinding participants?
A: No. The study does not argue that blinding is unimportant. Instead, it proposes a shift in focus: from perfect blinding to the management of expectations. Blinding is still a valuable tool, but it should be complemented by other strategies.

Q: What are the implications of this study for future research?
A: The study suggests that future trials should focus more on managing expectations and less on achieving perfect blinding. This could lead to more ethical and interpretable trials, which in turn could improve the quality of the data and the understanding of how psychedelics affect mental health.

Q: What is the real problem in psychedelic trials?
A: The real problem is not just that participants can guess their treatment. It’s that they might be disappointed when they find out they’re in the placebo group. This disappointment, known as lessebo, can have a measurable impact on the outcomes of the trial.

Sources

• ¶Redefining the real problem in psychedelic trials: Why fighting the Lessebo matters more than blinding integrity — International Journal of Drug Policy
• ¶Redefining the real problem in psychedelic trials: Why fighting the Lessebo matters more than blinding integrity — Europe PMC

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.